cas 2169266-67-3|| where to buy 5-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]oxypentanoic acid

Название продукции:5-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]oxypentanoic acid

IUPAC Name:5-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]oxy}pentanoic acid

: CAS：2169266-67-3; Молекулярная формула：C18H18N2O7; Чистота：95%

Упаковочная единица	Доступно для заказа	Цена ($)
CM1077428-100mg	in stock	ƴŽħ
CM1077428-250mg	in stock	Ǹƚǎ
CM1077428-500mg	in stock	řǟţƴ
CM1077428-1g	in stock	řǸţĳ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2169266-67-3 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:2169266-67-3; Молекулярная формула:C18H18N2O7; Точка плавления:-; Smiles-код:OC(=O)CCCCOC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1; Плотность:

: Номер в каталоге:CM1077428; Молекулярная масса:374.35; Точка кипения:; Номер Mdl:; Хранение:

: PROTAC-E3 Ligase Ligands; Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to be degraded via the ubiquitin–proteasome system. The advent of nonpeptidic small-molecule E3 ligase ligands revolutionized the field and ushered in the design of drug-like PROTACs with potent and selective degradation activity.; PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; Proteolysis-Targeting Chimeras | PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; PROTAC (Proteolysis-Targeting Chimeras) is a promising approach in drug discovery that involves the use of small molecules to target specific proteins for degradation by the cellular machinery.